Recent Actonel research results

Summaries and in some cases full abstracts of some Actonel research (Risedronate research studies).

• Actonel research:Two-year efficacy and tolerability of risedronate once a week for the treatment of women with post menopausal osteoporosis by Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP. University of California, San Francisco, California 94117, USA.

  Conclusion: "The 2-year data agree with the 1-year results demonstrating that the risedronate once-a-week doses are comparable in efficacy and safety to the 5 mg daily dose. Risedronate 35 mg once a week is considered the optimal dose want a once-a-week dosing regimen."

• Actonel research Risedronate for the prevention and treatment of postmenopausal osteoporosis . Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD, Guyatt G. Division of Rheumatology, Queen's University, Etherington Hall (Room 2004), Stuart street, Kingston, Ontario, CANADA, K7L 3N6.

  " BACKGROUND: Postmenopausal osteoporosis results in an increased susceptibility to low-trauma fractures due to reduced bone volume and microarchitectural deterioration. Risedronate, a third generation bisphosphonate, has been shown in multiple clinical trials to reduce fracture risk and improve bone mineral density in postmenopausal women with osteoporosis. First and second generation bisphosphonates are known to have gastrointestinal side-effects and risedronate may be better tolerated."

  "REVIEWER'S CONCLUSIONS: There is good evidence for the efficacy of risedronate in the reduction of both vertebral and non-vertebral fractures. In addition, there is evidence from randomized trials that risedronate is able to achieve this without increasing risk for overall withdrawals due to adverse effects. "

• Actonel research: Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg weekly for the treatment of postmenopausal women by E. Ilter, H. Karalok, EC Tufekci, O Batur of the Department of Gynecology and Obstetrics, Maltepe University Faculty of Medicine, Istanbul, Turkey and by published in Climacteric in April 2006 concluded that :” 35 mg given once per week has the same therapeutic efficacy and safety as a daily 5 mg regimen. Taking the medicine once a week is likely to be easier and more satisfactory than the daily regimen. However, patients taking a once-a-week regimen may forget to take it due to the 7-day break without medicine.”
• Actonel research: Importance of calcium co-medication in bisphosphonate therapy of osteoporosis : an approach to improving correct intake and drug adherence. By JD Ringe, SA van der Geest, G. Moller Medical Clinic 4, Klinikum Leverkusen, University of Cologne, Leverkusen, Germany and published in Drugs Aging. 2006.

  CONCLUSIONS: The availability of a fixed-combination pack of risedronic acid 35 mg/week and calcium tablets can increase the likelihood that postmenopausal osteoporotic patients will receive both a bisphosphonate and calcium, which in turn is likely to enhance the correct intake of combination therapy.

You can read the complete abstract of this and other studies about Actonel in Osteopenia or Osteoporosis at PubMed the web site of the National Center for Biotechnology Information by searching for Actonel research

To read about other Osteopenia treatments go to: Osteopenia treatments . Click here to read more about Medications